ZVSA (OTC)
ZYVERSA THERAPEUTICS INC
$0.240000
+0.000000 (+0.00%)
Prev close: $0.240000
Company Information
- Exchange
- OTC Link
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Stephen C. Glover
- Asset Type
- otc
- Website
- —
Fundamentals
- Market Cap
- $10.44M
- Employees
- 14
- P/E (TTM)
- -0.37
- P/B (TTM)
- 0.14
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
5
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2024 (Q3)
|
$-2.43 | $-3.77 | +1.3440 | +35.61% |
|
Jun 2024 (Q2)
|
$-3.31 | $-3.83 | +0.5150 | +13.46% |
|
Mar 2024 (Q1)
|
$-4.53 | $-3.77 | -0.7560 | -20.03% |
|
Dec 2023 (Q4)
|
$-136.80 | $-21.83 | -114.9720 | -526.72% |
Financial Statements
| Revenues | -$519.01K |
| Benefits Costs and Expenses | $26.03M |
| Costs And Expenses | $26.03M |
| Operating Expenses | $26.23M |
| Research and Development | $1.16M |
| Other Operating Expenses | $25.07M |
| Operating Income/Loss | -$26.23M |
| Income/Loss From Continuing Operations After Tax | -$26.56M |
| Income/Loss From Continuing Operations Before Tax | -$26.55M |
| Interest Income/Expense After Provision For Losses | -$519.01K |
| Interest Income/Expense Operating, Net | -$519.01K |
| Net Income/Loss | -$25.70M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$25.70M |
| Net Income/Loss Available To Common Stockholders, Basic | -$25.70M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Provision For Loan, Lease, And Other Losses | $0.00 |
| Basic Earnings Per Share | -$3.32 |
| Diluted Earnings Per Share | -$3.32 |
| Basic Average Shares | 5,531,284 |
| Diluted Average Shares | 5,531,284 |
| Assets | $1.04M |
| Current Assets | $995.53K |
| Noncurrent Assets | $44.73K |
| Liabilities | $12.77M |
| Current Liabilities | $12.77M |
| Accounts Payable | $9.81M |
| Other Current Liabilities | $2.96M |
| Noncurrent Liabilities | $0.00 |
| Equity | -$11.73M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$11.73M |
| Liabilities And Equity | $1.04M |
| Net Cash Flow From Operating Activities | -$5.96M |
| Net Cash Flow From Operating Activities, Continuing | -$5.96M |
| Net Cash Flow From Investing Activities | -$405.06K |
| Net Cash Flow From Investing Activities, Continuing | -$405.06K |
| Net Cash Flow From Financing Activities | $6.36M |
| Net Cash Flow From Financing Activities, Continuing | $6.36M |
| Net Cash Flow | $0.00 |
| Net Cash Flow, Continuing | $0.00 |
| Comprehensive Income/Loss | -$25.70M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$25.70M |
| Other Comprehensive Income/Loss | $0.00 |